12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xalkori crizotinib: Phase I data

An open-label, North American Phase I trial in patients aged 1-21 with relapsed or refractory ALK-driven tumors showed that Xalkori produced 7 complete responses in 8 evaluable patients with ALCL. Additionally, 2 patients with neuroblastoma had complete responses and 2 patients had partial responses - 1 with an inflammatory myofibroblastic tumor and 1 with non-small cell lung cancer (NSCLC)....

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >